Laekna, Inc. (LAEKF)

Market Cap	372.52M -46.4%
Revenue (ttm)	37.83M
Net Income	-15.05M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Open	0.9075
Previous Close	0.7593
Day's Range	0.9075 - 0.9075
52-Week Range	0.7300 - 1.1900
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 25, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative brea...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: Cayman Islands
• Stock Exchange: OTCMKTS
• Ticker Symbol: LAEKF

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 25, 2026

Data Sources Report a data error